Advertisement

Topics

First Potential Gene Therapy for Hemophilia B Restores Blood Clotting in Phase II

09:06 EDT 14 May 2019 | Labiotech.eu

A gene therapy developed by the Dutch biotech uniQure increased the activity of a blood clotting protein enough to stop bleeds in patients with the blood disorder hemophilia B. Hemophilia B is a rare genetic condition in which patients have a mutation in the blood clotting protein factor IX (FIX), reducing its activity below 6% […]

The post First Potential Gene Therapy for Hemophilia B Restores Blood Clotting in Phase II appeared first on Labiotech.eu.

Original Article: First Potential Gene Therapy for Hemophilia B Restores Blood Clotting in Phase II

NEXT ARTICLE

More From BioPortfolio on "First Potential Gene Therapy for Hemophilia B Restores Blood Clotting in Phase II"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...